![Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial ... Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e0b02067-6dfb-4484-850c-860646eb6001/gr3b_lrg.gif)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial ...
![The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O010 – O169) | Bone Marrow Transplantation The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O010 – O169) | Bone Marrow Transplantation](https://media.springernature.com/relative-r300-703_m1050/springer-static/image/art%3A10.1038%2Fs41409-021-01342-6/MediaObjects/41409_2021_1342_Figp_HTML.png)
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O010 – O169) | Bone Marrow Transplantation
![Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial ... Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f66b463d-0f51-429c-8a3b-87531356ab5d/gr3a_lrg.gif)